ATE102838T1 - Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel. - Google Patents
Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel.Info
- Publication number
- ATE102838T1 ATE102838T1 AT90107246T AT90107246T ATE102838T1 AT E102838 T1 ATE102838 T1 AT E102838T1 AT 90107246 T AT90107246 T AT 90107246T AT 90107246 T AT90107246 T AT 90107246T AT E102838 T1 ATE102838 T1 AT E102838T1
- Authority
- AT
- Austria
- Prior art keywords
- agent
- treatment
- neoplasm
- compositions
- side effect
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 208000035269 cancer or benign tumor Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000009826 neoplastic cell growth Effects 0.000 title 1
- 239000003223 protective agent Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 6
- 229960004679 doxorubicin Drugs 0.000 abstract 3
- 229940034982 antineoplastic agent Drugs 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 238000009096 combination chemotherapy Methods 0.000 abstract 2
- 230000001120 cytoprotective effect Effects 0.000 abstract 2
- KPRFMAZESAKTEJ-UHFFFAOYSA-N 2-[1-amino-4-[2,5-dioxo-4-(1-phenylethyl)pyrrolidin-3-yl]-1-oxobutan-2-yl]-5-carbamoylheptanedioic acid;azane Chemical compound [NH4+].[NH4+].C=1C=CC=CC=1C(C)C1C(CCC(C(CCC(CC([O-])=O)C(N)=O)C([O-])=O)C(N)=O)C(=O)NC1=O KPRFMAZESAKTEJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 229950005155 carbetimer Drugs 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33950389A | 1989-04-17 | 1989-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE102838T1 true ATE102838T1 (de) | 1994-04-15 |
Family
ID=23329296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT90107246T ATE102838T1 (de) | 1989-04-17 | 1990-04-17 | Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0393575B1 (de) |
| JP (1) | JPH02292227A (de) |
| AT (1) | ATE102838T1 (de) |
| CA (1) | CA2014732A1 (de) |
| DE (1) | DE69007319T2 (de) |
| DK (1) | DK0393575T3 (de) |
| ES (1) | ES2062155T3 (de) |
| PT (1) | PT93772A (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| US5371199B1 (en) * | 1992-08-14 | 1995-12-26 | Univ Pennsylvania | Substituted porphyrins porphyrin-containing polymers and synthetic methods therefor |
| US5817830A (en) * | 1992-08-14 | 1998-10-06 | Trustees Of The University Of Pennsylvania | Pyrrolic compounds |
| US5599924A (en) * | 1992-08-14 | 1997-02-04 | Trustees Of The University Of Pennsylvania | Electron-deficient porphyrins and processes and intermediates for preparing same |
| US5493017A (en) * | 1992-08-14 | 1996-02-20 | The Trustees Of The University Of Pennsylvania | Ring-metalated porphyrins |
| US5378456A (en) * | 1993-03-25 | 1995-01-03 | American Cyanamid Company | Antitumor mitoxantrone polymeric compositions |
| US5569667A (en) * | 1995-01-19 | 1996-10-29 | Warner-Lambert Company | Treatment of prostate cancer |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| US6265385B1 (en) | 1996-01-11 | 2001-07-24 | Topo Target Aps | Topoisomerase II poison and bis-dioxopiperazine derivative combination therapy |
| EP0874630B1 (de) * | 1996-01-11 | 2003-08-20 | TopoTarget ApS | Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten |
| ATE310505T1 (de) * | 1996-05-14 | 2005-12-15 | Stanislaw R Burzynski | Liposomale antineoplaston therapie mit bemerkenswert verbesserter antineoplastischer aktivität |
| DE19636889A1 (de) | 1996-09-11 | 1998-03-12 | Felix Dr Kratz | Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel |
| US5783689A (en) * | 1996-11-12 | 1998-07-21 | University Of Notre Dame | Antibacterial and antifungal nucleosides |
| GB9804013D0 (en) | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
| US6767926B1 (en) | 1999-10-12 | 2004-07-27 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| AU780844B2 (en) * | 1999-10-12 | 2005-04-21 | Temple University-Of The Commonwealth System Of Higher Education | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| AT408719B (de) * | 2000-03-22 | 2002-02-25 | Nowicky Wassili | Mittel zur behandlung von hepatitis c |
| AU2001258628A1 (en) | 2000-05-31 | 2001-12-11 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| US20020128258A1 (en) * | 2001-03-09 | 2002-09-12 | Jean-Pierre Robin | Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| US8563592B2 (en) | 2001-11-01 | 2013-10-22 | Spectrum Pharmaceuticals, Inc. | Bladder cancer treatment and methods |
| AU2002350115A1 (en) | 2001-11-01 | 2003-05-12 | Spectrum Pharmaceuticals, Inc. | Medical compositions for intravesical treatment of bladder cancer |
| EP1463487B1 (de) * | 2001-12-19 | 2010-05-19 | Research Development Foundation | Liposomale abgabe von verbindungen auf vitamin-e-basis |
| JP2005532280A (ja) | 2002-04-03 | 2005-10-27 | アストラゼネカ アクチボラグ | 化合物 |
| FR2863892B1 (fr) * | 2003-12-18 | 2007-05-11 | Univ Paris Descartes | Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux |
| WO2005111055A1 (ja) * | 2004-04-28 | 2005-11-24 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | 新規抗生物質キガマイシン類とその用途 |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| EP3431142B1 (de) | 2011-08-30 | 2020-06-17 | Astex Pharmaceuticals, Inc. | Decitabinderivatformulierungen |
| WO2014179528A2 (en) * | 2013-05-01 | 2014-11-06 | Brown Dennis M | Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions |
| AU2016287585B2 (en) | 2015-07-02 | 2020-12-17 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| RU2020108580A (ru) | 2017-08-03 | 2021-09-03 | Оцука Фармасьютикал Ко., Лтд. | Лекарственное соединение и способы его очистки |
| CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255537A (en) * | 1979-01-22 | 1981-03-10 | Monsanto Company | Polymeric immunoregulatory agents containing half-amide/half carboxy/imide groups |
-
1990
- 1990-04-16 PT PT93772A patent/PT93772A/pt not_active Application Discontinuation
- 1990-04-17 DK DK90107246.2T patent/DK0393575T3/da active
- 1990-04-17 DE DE69007319T patent/DE69007319T2/de not_active Expired - Fee Related
- 1990-04-17 JP JP2101530A patent/JPH02292227A/ja active Pending
- 1990-04-17 EP EP90107246A patent/EP0393575B1/de not_active Expired - Lifetime
- 1990-04-17 CA CA002014732A patent/CA2014732A1/en not_active Abandoned
- 1990-04-17 AT AT90107246T patent/ATE102838T1/de not_active IP Right Cessation
- 1990-04-17 ES ES90107246T patent/ES2062155T3/es not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2014732A1 (en) | 1990-10-17 |
| EP0393575A1 (de) | 1990-10-24 |
| DE69007319T2 (de) | 1994-08-04 |
| JPH02292227A (ja) | 1990-12-03 |
| DE69007319D1 (de) | 1994-04-21 |
| DK0393575T3 (da) | 1994-04-05 |
| PT93772A (pt) | 1991-01-08 |
| ES2062155T3 (es) | 1994-12-16 |
| EP0393575B1 (de) | 1994-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE102838T1 (de) | Zusammensetzungen zur behandlung von neoplasia mit gehalt an neoplasmushemmendem mittel und nebenwirkungen reduzierendem schutzmittel. | |
| LV10924A (lv) | Sintetiskie katalitiskie brivo radikalu akceptori kurus izmanto ka antioksidantus slimibu profilaksei un arstesanai | |
| PT671910E (pt) | Utilizacao de derivados de adamantano no fabrico de um medicamento para o tratamento do glaucoma | |
| DK0612248T3 (da) | Præparat, der indeholder cisplatin og topotecan som antitumormiddel | |
| SE9301951D0 (sv) | Methods for administration of taxol | |
| EP2295063A8 (de) | Zusammensetzungen und deren Verwendung zur Behandlung von Erkrankungen der Mitochondrien | |
| EP0690722A4 (de) | Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren | |
| MXPA02002681A (es) | Uso de metabolitos de acido alfa-linolenico para el tratamiento o prevencion del cancer. | |
| ATE338553T1 (de) | Antitumorkombination aus 3-amino-1,2,4- benzotriazine 1,4-dioxid/paclitaxel/platin | |
| OA09917A (en) | Compounds for use in treating HIV infection | |
| DE69803773D1 (de) | Yohimbine und arginin enthaltende zusammensetzung zur behandlung der erektilen fehlfunktion | |
| DK0701440T3 (da) | Tri(platin)komplekser | |
| ITRM910730A1 (it) | Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici, indicate nella terapia dei tessuti superficiali. | |
| IL118218A0 (en) | Terpenoidic derivatives and pharmaceutical compositions containing them | |
| ES2012547A6 (es) | Procedimiento para preparar una composicion farmaceutica que contiene metaloporfirinas. | |
| DE3273389D1 (en) | Derivatives of pentacyclo undecanes, processes for preparing these compounds, and pharmeceutical compositions thereof | |
| ES8704903A1 (es) | Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido. | |
| EP1374873B8 (de) | Verwendung von n-acetyl-d-glucosamin bei der herstellung eines arzneimittels zur unterdrückung der nebenwirkungen von strahlentherapie und chemotherapie | |
| EP0173145A3 (en) | Reduction of the toxic effects caused by anthraquinone drugs | |
| ATE206056T1 (de) | Therapeutisches agens für neutropenie | |
| IL98200A0 (en) | Pharmaceutical composition containing a derivative of substituted-l-valyl-l-prolinamide | |
| OA09771A (en) | Asphodelus composition for increasing white blood cell count. | |
| GR3029898T3 (en) | Use of Etofibrate and pharmaceutical compositions containing etofibrate in the treatment of diabetic angio- and retinopathy. | |
| ATE227573T1 (de) | Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring | |
| JO1708B1 (en) | The use of trinitrobenzene or cochineal acid in the treatment of cancer or genital diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |